Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in…
Gilead Sciences, Inc. and Galapagos NV announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and…
Read More...
Read More...
